Altria Group Inc.

MO
Financial Analysis · Updated May 12, 2026 · Coverage 2026-Q2
Latest Q Revenue
$5.4B
Q1 2026 · +3.2% YoY
Margin Profile
Gross 60%
Operating 55%
FCF 42%
FY2024
Net Debt
$21.0B
Cash $3.0B · Debt $24.0B · FY2025
Diluted Shares
1.69B
FY2024

Business Overview

ticker: MO step: 01 generated: 2026-05-12 source: quick-research

Altria Group, Inc. (MO) — Business Overview

Business Description

Altria is the largest US-focused tobacco company, anchored by Marlboro (the leading US premium cigarette) and a portfolio of smoke-free products (on! and on! PLUS nicotine pouches, NJOY e-vapor, USSTC moist smokeless tobacco). The company is mid-execution on a "smoke-free transition" to offset structural cigarette volume decline (~5% annual). However, the smoke-free strategy faces headwinds: NJOY took $2.2B in impairment charges in 2025 + ITC exclusion order makes 2026 US comeback nearly impossible; on! is losing share to PMI's ZYN. CEO Billy Gifford.

Revenue Model

  • Smokeable Products (~85% of revenue): Cigarettes (Marlboro, L&M, Parliament, Virginia Slims, Basic, Chesterfield) + cigars (Black & Mild via John Middleton)
  • Oral Tobacco Products (~12%): USSTC moist smokeless (Copenhagen, Skoal, Husky) + on!/on! PLUS nicotine pouches (Helix Innovations)
  • All Other (~3%): NJOY (e-vapor, impaired), Horizon Innovations JV (heated tobacco — IQOS-like)
  • Premium pricing strategy on Marlboro offsets volume decline

Products & Services

Smokeable Products
  • Marlboro: #1 premium US cigarette (59.5% premium segment share; 39.7% total US share)
  • L&M, Parliament, Virginia Slims, Basic, Chesterfield: Other PM USA brands
  • Black & Mild cigars (John Middleton)
  • April 2026: Raised Marlboro prices $0.20-0.25/pack
  • April 2026: Raised L&M prices $0.20/pack
Smoke-Free Portfolio (strategic pivot)
  • on! / on! PLUS nicotine pouches: Volume +17.6%; on! PLUS first FDA pilot program authorization; 58.1% oral tobacco market share
  • USSTC moist smokeless: Copenhagen, Skoal, Husky (declining category)
  • NJOY e-vapor: ACE device facing ITC exclusion; took $2.2B impairment in 2025
  • Horizon Innovations (with KT&G): US heated tobacco joint venture
  • Helix ROW: Rest-of-world nicotine pouches

Customer Base & Go-to-Market

  • Adult tobacco consumers (US only): Direct to retail stores (convenience, supermarket, drug)
  • Distribution: McLane + other CPG wholesalers
  • Geographic mix: ~100% US
  • Major retailers: Convenience stores (~80%), grocery (~10%), drug (~5%), military/other (~5%)

Competitive Position

Altria is the #1 US cigarette company by market share (~46% total), with Marlboro dominating premium (59.5%). Moats: (1) Marlboro's iconic brand + ~60% premium pricing power, (2) US-only focus = regulated franchise (no FX, no international politics), (3) industry-leading smokeable operating margins ~65%. However, smoke-free transition is lagging vs. Philip Morris International (PMI), which spun off from Altria in 2008 and now dominates ZYN (70%+ pouch share) + IQOS internationally. Competitors: PMI (ZYN, IQOS), British American Tobacco (Newport menthol via Reynolds), JTI, Imperial.

Key Facts

  • Founded: 1985 (as Philip Morris Companies); rebranded Altria Group 2003; spun off PMI 2008
  • Headquarters: Richmond, VA
  • Employees: ~6,500
  • Exchange: NYSE
  • Sector / Industry: Consumer Staples / Tobacco
  • Market Cap: ~$95B (May 2026)
  • CEO: William F. "Billy" Gifford (since 2021)
  • Dividend: $4.24 annual ($1.06 quarterly)
  • 57+ consecutive years of dividend growth (Dividend King)
  • 6.5%+ dividend yield
  • $2.2B NJOY impairment in 2025

Financial Snapshot

ticker: MO step: 04 generated: 2026-05-12 source: quick-research

Altria Group, Inc. (MO) — Financial Snapshot

Income Statement Summary

Metric FY2023 FY2024 FY2025 YoY
Net Revenue $20.5B $20.4B $20.7B +2%
Adjusted Operating Margin (Smokeable) 62% 64% 65.1% +110bps
Adjusted EPS $4.95 $5.12 $5.42 +6%
Free Cash Flow $8B $8B $8B flat

Q1 2026 Highlights

Metric Q1 2026 YoY
Adj EPS $1.32 beat $1.25 est
Net Revenue $5.43B +3.2%
Smokeable Pricing +9-10% Marlboro price hike
Cigarette Industry Volume -5% YoY structural decline
Marlboro Retail Share 39.7% (-1.4 pts) Q1 erosion
on! Category Share 13.4% (-4.2 pts) losing to ZYN
on! Volume +17.6% absolute volume up

Q2 2026 Highlights

Metric Q2 2026 YoY
Revenue $4.76B beat by 3.94%
EPS beat by 5.6%

2026 Guidance (mgmt reaffirmed)

Metric 2026 Guide
Adj. EPS $5.56-5.72 (+2.5-5.5% vs $5.42 in 2025)
Dividend Growth mid-single-digit (~3-5%)

Product Detail

Product Status
Marlboro 59.5% premium segment; 39.7% total; price hike Apr 2026
on! PLUS First FDA pilot program authorization; nationwide retail March 2026
NJOY ACE ITC exclusion order; cannot return to US in 2026; impaired
USSTC (Copenhagen, Skoal) Declining category

Cash Flow & Balance Sheet (FY2025)

Metric Value
Operating Cash Flow ~$9B
Capital Expenditures ~$300M
Free Cash Flow ~$8.5B
Cash & Equivalents ~$3B
Total Debt ~$24B
Net Debt/EBITDA ~1.8x

Key Ratios (approximate, May 2026)

  • P/E (forward): ~10x | EV/EBITDA: ~9x | Dividend Yield: ~6.5%
  • FCF Yield: ~9%
  • Payout Ratio: ~75%

Forward Estimates

  • FY2026E Revenue: ~$21B (+1-2%)
  • FY2026E Adj EPS: $5.56-5.72 (mgmt; +2.5-5.5%)
  • FY2027E EPS: ~$5.85 (+3-5%)
  • FY2028E EPS: ~$6.10 (modest growth as smokeable continues declining)

Capital Return

  • Dividend $4.24 annual = ~$7B paid — 6.5% yield
  • 57+ consecutive years of dividend growth (Dividend King — highest yield)
  • Buybacks: $1-2B annual run rate
  • Total capital return: ~$8B annual
  • Combined yield: ~8.5%

Deeper Financial Analysis

The fundamental tier adds 9 additional research dimensions for $MO.

Revenue Breakdown
Segment revenue, geographic mix, product-line contribution margins, and cohort dynamics.
Financial Trends
Quarter-over-quarter momentum, leading indicators, and inflection point analysis.
Balance Sheet
Debt structure, liquidity runway, dilution risk, and working capital dynamics.
Capital Allocation
Buyback cadence, M&A appetite, dividend policy, and reinvestment priorities.
Returns on Capital (ROIC)
Multi-year ROIC vs. WACC, marginal returns on reinvestment, sales-to-invested-capital efficiency, and moat spread.
GET /api/v1/research/MO/fundamental$1.00 · Bearer token required
Markdown: /stocks/mo/financials/md · → thesis · → memo